Form 4: Teva Pharma Executive Sells Shares

Christine Fox, EVP of U.S. Commercial at Teva Pharmaceutical Industries Ltd., reported the sale of 21,258 ordinary shares.

Summary

• Christine Fox, an Executive Vice President at Teva Pharmaceutical Industries Ltd., has reported a transaction involving the sale of company shares.
• The transaction, which occurred on April 30, 2026, involved the disposal of 21,258 ordinary shares.
• The sale was executed at a weighted average price of $35.31 per share, with individual transactions ranging from $35.28 to $35.33.
• Following this transaction, Ms. Fox beneficially owns 63,647 ordinary shares directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to an executive selling shares, though the sale is within a typical range and could be for personal reasons.

Negatives

• An executive officer has sold a significant number of shares, which could be interpreted negatively by the market.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings, which report changes in beneficial ownership by insiders, are common for executives. While sales can sometimes signal a lack of confidence, they can also be for personal financial planning reasons. The context of the sale, such as the executive's tenure and overall compensation structure, is crucial for a complete interpretation.

Stakeholder Impact

• Shareholders may view the sale by an executive as a potential negative signal, although the reasons for the sale are not disclosed.
• The transaction does not appear to directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Teva Pharmaceutical Industries, Form 4, Insider Trading, Share Sale, Christine Fox, Securities Exchange Act